Heather McKenzie is a Senior Editor at BioSpace. With over five years of experience in the biopharmaceutical industry, she specializes in neuroscience, gene therapy, and pharmaceutical regulation, while also covering topics such as immunology, oncology, and mental health care. Her work has been featured in NewsBreak, ESG Investor, AM850 WRUF, and WUFT News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Heather's coverage is predominantly focused on the healthcare and pharmaceutical industry, with a specific emphasis on FDA approvals, gene therapy, CRISPR technology, drug development, Alzheimer's disease, and CNS diseases. Her articles heavily cite data and press releases.
Given Heather’s focus on citing data and press releases in her articles about healthcare and pharmaceuticals, she may be interested in receiving pitches from experts who can provide statistical analysis or insights based on solid scientific evidence related to these topics. Pitches offering access to exclusive data or early access to research findings could also be appealing.
Heather does not appear to have a specific geographic focus but rather seems to cover global developments within the healthcare and pharmaceutical industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Heather-Mckenzie
First quarter earnings continue to arrive, with analysts demanding more from cautious Pfizer and Eli Lilly expecting more revenue; the FDA taps Katherine Szarama as Vinay Prasad's controversial FDA tenure ends; oncology veterans miss Richard Pazdur at the agency's first adcomm in nine months; and QurAlis and Corcept Therapeutics spark renewed hope in ALS.
By: Heather-Mckenzie
President Donald Trump has reportedly signed off on a plan to fire FDA Commissioner Marty Makary, who has overseen a tumultuous period at the agency
It's official: FDA Commissioner Marty Makary is out at the FDA after reports of his ouster emerged late last week; Sanofi is reportedly having challenges with one of the FDA's new signature programs; and biopharma CEOs' multimillion-dollar salaries ticked up again this year. Who made the most in 2025?
By: Heather-Mckenzie
Last month, Revolution Medicines' RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech's heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve on that result with increased tolerability—and more time for patients.
By: Heather-Mckenzie
A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said Revolution Medicines “is evolving into a major revenue-generating oncology company,” and projects an approval in second-line disease by the end of the third quarter.
Eli Lilly's obesity pill Foundayo—generic name orforglipron— won FDA approval on April 1, adding another chapter to the epic battle for the weight
By: Heather-Mckenzie, Gabrielle-Masson
Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma's top paid CEOs make up to 358 times more than their employees; Revolution Medicine's pancreatic cancer results highlight movement in the deadly disease space; more.
By: Heather-Mckenzie
FDA veteran Richard Pazdur outlined his priorities for the next FDA commissioner but stopped short of putting himself forward as a candidate to lead the agency at an RBC Capital Markets event on Tuesday.
By: Heather Mckenzie
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
By: Heather-Mckenzie
The FDA's priority review acceptance of BridgeBio's BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in muscular dystrophy more broadly.
